PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7:

C07D 235/30, 417/04, 403/10, 417/12, 219/08, 255/04, 239/42, 487/18, 235/20, 279/18, A61K 31/415, 31/425, 31/435, 31/395, 31/505, 31/155

(11) International Publication Number:

WO 00/01676

(43) International Publication Date:

13 January 2000 (13.01.00)

(21) International Application Number:

PCT/DK99/00378

A1

(22) International Filing Date:

1 July 1999 (01.07.99)

(30) Priority Data:

PA 1998 00865

2 July 1998 (02.07.98)

DK

(71) Applicant (for all designated States except US): NEU-ROSEARCH A/S [DK/DK]; Patent Dept., Pederstrupvej 93, DK-2750 Ballerup (DK).

(72) Inventors; and

- (75) Inventors/Applicants (for US only): TEUBER, Lene [DK/DK];
 NeuroSearch A/S, Pederstrupvej 93, DK-2750 Ballerup
 (DK). OLESEN, Søren-Peter [DK/DK]; NeuroSearch A/S,
 Pederstrupvej 93, DK-2750 Ballerup (DK). STRØBÆK,
 Dorte [DK/DK]; NeuroSearch A/S, Pederstrupvej 93,
 DK-2750 Ballerup (DK). JENSEN, Bo, Skaaning
 [DK/DK]; NeuroSearch A/S, Pederstrupvej 93, DK-2750
 Ballerup (DK). PETERS, Dan [SE/SE]; NeuroSearch A/S,
 Pederstrupvej 93, DK-2750 Ballerup (DK).
- (74) Agent: NEUROSEARCH A/S; Patent Dept., Pederstrupvej 93, DK-2750 Ballerup (DK).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

(54) Title: POTASSIUM CHANNEL BLOCKING AGENTS

(57) Abstract

This invention relates to novel potassium channel blocking agents, and their use in the preparation of pharmaceutical compositions. Moreover the invention is directed to pharmaceutical compositions useful for the treatment or alleviation of diseases or disorders associated with the activity of potassium channels, in particular asthma, cystic fibrosis, chronic obstructive pulmonary disease and rhinorrhea, convulsions, vascular spasms, coronary artery spasms, renal disorders, polycystic kidney disease, bladder spasms, urinary incontinence, bladder outflow obstruction, irritable bowel syndrome, gastrointestinal dysfunction, secretory diarrhoea, ischaemia, cerebral ischaemia, ischaemic heart disease, angina pectoris, coronary heart disease, traumatic brain injury, psychosis, anxiety, depression, dementia, memory and attention deficits, Alzheimer's disease, dysmenorrhea, narcolepsy, Reynaud's disease, intermittent claudication, Sjorgren's syndrome, migraine, arrhythmia, hypertension, absence seizures, myotonic muscle dystrophia, xerostomi, diabetes type II, hyperinsulinemia, premature labour, baldness, cancer, and immune suppression.